Regenxbio (RGNX) Other Accumulated Expenses (2014 - 2025)

Regenxbio's Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $757000.0 for Q4 2025.

• On a quarterly basis, Other Accumulated Expenses rose 16.64% year-over-year to $757000.0 in Q4 2025; TTM through Dec 2025 was $757000.0, a 16.64% increase from a year earlier, with the FY2025 full-year figure at $757000.0, up 16.64% from the prior year.
• Other Accumulated Expenses declined to $757000.0 in Q4 2025 per RGNX's latest filing, from $929000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $999000.0 in Q1 2023 and bottomed at $122000.0 in Q1 2021.
• The 5-year median for Other Accumulated Expenses is $748000.0 (2022), against an average of $697500.0.
• Biggest YoY gain for Other Accumulated Expenses was 363.44% in 2021; the steepest drop was 58.64% in 2021.
• Year by year, Other Accumulated Expenses stood at $744000.0 in 2021, then gained by 0.27% to $746000.0 in 2022, then slumped by 38.61% to $458000.0 in 2023, then soared by 41.7% to $649000.0 in 2024, then grew by 16.64% to $757000.0 in 2025.
• Per Business Quant, the three latest RGNX Other Accumulated Expenses figures stand at $757000.0 (Q4 2025), $929000.0 (Q3 2025), and $736000.0 (Q2 2025).